Biomarker panel to differentiate stroke from stroke mimic

描述(申请人提供)：在美国，中风每年影响超过70万人，是第三大致死原因。中风患者在急诊室可能会出现各种各样的症状，这些症状可能是由其他与中风无关的疾病引起的，统称为中风模拟。即使在最先进的中风中心，在通过成像排除出血性病变后，临床检查也能做出缺血性中风的诊断。这些成像测试可以用来诊断出血性中风，但在检测大多数缺血性中风时相对无效。一种可靠、快速地区分卒中和拟卒中的方法对于当前的检查和基于影像的卒中诊断是必要的，随着对缺血性卒中时间关键治疗的新疗法的实施，这种方法将变得更加关键。与心血管疾病和肿瘤学相比，没有获得批准的免疫分析或分子测试可用于辅助诊断。对以前的数据集的分析表明，我们先进的Generx算法技术能够开发出准确的诊断模型，而其他多标记面板则无法做到这一点。在这个第一阶段的提案中，我们将进行一项验证性研究，从200名确诊为中风样症状并被诊断为中风或模仿中风的患者中采集血液样本。我们将测量出现在我们先前研究的顶级组合和算法中的中风生物标记物蛋白质水平标记物，并利用我们专有的Generx技术开发多标记物预测模型，用于准确区分中风和模拟中风。项目简介：目前还没有血液测试可以帮助准确诊断中风患者。这项研究开发了一种诊断方法，以帮助区分中风患者和许多来到急诊室时有中风样症状的非中风患者。这种诊断方法的成功开发将提高中风治疗的有效性和速度，从而增加患者改善的机会和治疗的安全性。

DESCRIPTION (provided by applicant): In the United States (US), stroke affects more than 700,000 people annually in the U.S. and is the third leading cause of death. Stroke patients may present to the emergency room with a wide variety of symptoms that can be caused by other conditions not related to stroke, collectively called stroke mimic. Even at the most advanced stroke centers, the diagnosis of ischemic stroke is made by clinical examination after ruling out hemorrhagic lesions by imaging. These imaging tests can be used to diagnose hemorrhagic stroke but is relatively ineffective in detecting most ischemic stroke. A reliable and rapid method to distinguish stroke and stroke mimic is a necessary aid to current examination and imaging-based stroke diagnosis and will become more crucial with the implementation of new therapies for the time-critical treatment of ischemic stroke. In contrast to cardiovascular disease and oncology, no approved immunoassay or molecular test is available to aid diagnosis. Analysis of a previous dataset demonstrated that our advanced GeneRx algorithm technologies were able to develop an accurate diagnostic model where other multi-marker panels failed. In this phase I proposal we will perform a validation study, collecting blood samples from 200 admitted with stroke-like symptoms and diagnosed as stroke or stroke mimic. We will measure stroke biomarker protein levels markers present in the top combinations and algorithms from our previous study, and utilize our proprietary GeneRx technology to develop a multiple marker predictive model for accurate differentiation of stroke from stroke mimic. Project Narrative: Currently no blood test is available to help accurately diagnose stroke patients. This study develops a diagnostic to help differentiate stroke patients from the many non-stroke patients that arrive at the ER with stroke-like symptoms. Successful development of this diagnostic will increase the effectiveness and speed of stroke treatment to increase a patient's chances of improvement and safety of treatment.